# Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

> **NCT03071133** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 344 (actual)

## Conditions studied

- Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03071133
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-01-08
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071133, "Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03071133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*